Literature DB >> 8215926

Machado-Joseph disease of Azorean ancestry in Brazil: the Catarina kindred. Neurological, neuroimaging, psychiatric and neuropsychological findings in the largest known family, the "Catarina" kindred.

J Radvany1, C H Camargo, Z M Costa, N C Fonseca, E D Nascimento.   

Abstract

At the moment 9 seemingly independent families with the clinical diagnosis of MJD are known in Brazil. The largest family tree of Azorean ancestry contains 622 individuals in 9 generations. 236 were examined, 39 found to be affected by two examiners. Phenotypes I, II and III were expressed by 12, 23 and 4 patients with age of onset by phenotypes being 10-48, 14-54 and 30-55 respectively. Although clinically more severe, juvenile onset type I disease did not show as severe a ponto-mesencephalic atrophy on MRI as the father with type II disease of similar symptomatic duration. None of the 8 patients examined with MRI showed olivary atrophy or pallidal abnormalities. 12 affected and 23 at risk were evaluated with neuropsychological tests. Attention was normal in both groups. Verbal memory scores were below normal in the affected and there was greater decay with time than in the risk group. Both scored below normal in identifying silluettes and constructional praxis. Visual memory scores were well below normal for both, with many rotations but no omissions or confabulations. A peculiar pattern of multiplying internal details called "the fly-eye effect" was observed in 6 affected and 8 at risk. Defective color distinction when multiple colors presented close to each other, in face of proper naming of individual colors ("color simulatanagnosia"), was looked for in 29 people. 4/10 affected and 4/19 at risk showed this phenomenon. Cognitive dysfunctions in this MJD family are prominent in the sphere of vision. Whether they constitute an early manifestation in those at risk and thus serve as a clinical identifier of the illness is yet to be established. Depression was looked for in the history of the family with DSM III-R criteria and an attempt at quantification with the Montgomery-Asberg Rating Scale. There was no significant quantitative difference between affected and at risk. Once undeniably symptomatic however, the patients had no, or less depression than themselves before or at the early stages of the illness. Covert depression was appropriately excluded. Fully established MJD in this family seemed to exert a protective effect from depression.

Entities:  

Mesh:

Year:  1993        PMID: 8215926     DOI: 10.1590/s0004-282x1993000100004

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  14 in total

1.  Cognitive deficits in Machado-Joseph disease correlate with hypoperfusion of visual system areas.

Authors:  Pedro Braga-Neto; Lívia Almeida Dutra; José Luiz Pedroso; André C Felício; Helena Alessi; Ruth F Santos-Galduroz; Paulo Henrique F Bertolucci; Mário Luiz V Castiglioni; Rodrigo Affonseca Bressan; Griselda Esther Jara de Garrido; Orlando Graziani Povoas Barsottini; Andrea Jackowski
Journal:  Cerebellum       Date:  2012-12       Impact factor: 3.847

2.  Cognition in SCA21 reflects developmental and adult onset cerebellar cognitive affective syndrome.

Authors:  Pedro Braga-Neto; José Luiz Pedroso; Orlando G P Barsottini; Jeremy D Schmahmann
Journal:  Brain       Date:  2015-01-08       Impact factor: 13.501

Review 3.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

4.  Neurophysiological studies and non-motor symptoms prior to ataxia in a patient with machado-joseph disease: trying to understand the natural history of brain degeneration.

Authors:  José Luiz Pedroso; Edson Bor-Seng-Shu; Pedro Braga-Neto; Rodrigo Souza Ribeiro; Márcio Luiz Escorcio Bezerra; Lucila B F do Prado; Ilza Rosa Batista; Helena Alessi; Manoel Jacobsen Teixeira; Gilberto Mastrocola Manzano; Gilmar Fernandes do Prado; Orlando Graziani Povoas Barsottini
Journal:  Cerebellum       Date:  2014-08       Impact factor: 3.847

5.  Cerebellar cognitive affective syndrome in Machado Joseph disease: core clinical features.

Authors:  Pedro Braga-Neto; José Luiz Pedroso; Helena Alessi; Lívia Almeida Dutra; André Carvalho Felício; Thaís Minett; Patrícia Weisman; Ruth F Santos-Galduroz; Paulo Henrique F Bertolucci; Alberto Alain Gabbai; Orlando Graziani Povoas Barsottini
Journal:  Cerebellum       Date:  2012-06       Impact factor: 3.847

6.  Cognitive and social cognitive functioning in spinocerebellar ataxia : a preliminary characterization.

Authors:  P Garrard; N H Martin; P Giunti; L Cipolotti
Journal:  J Neurol       Date:  2008-03-20       Impact factor: 4.849

7.  Machado Joseph disease maps to the same region of chromosome 14 as the spinocerebellar ataxia type 3 locus.

Authors:  E C Twist; L K Casaubon; M H Ruttledge; V S Rao; P M Macleod; J Radvany; Z Zhao; R N Rosenberg; L A Farrer; G A Rouleau
Journal:  J Med Genet       Date:  1995-01       Impact factor: 6.318

8.  Widespread neuronal damage and cognitive dysfunction in spinocerebellar ataxia type 3.

Authors:  Tátila Martins Lopes; Anelyssa D'Abreu; Marcondes Cavalcante França; Clarissa Lin Yasuda; Luiz Eduardo Betting; Adriana Bastos Samara; Gabriela Castellano; Júlio César Somazz; Marcio Luiz Figueredo Balthazar; Iscia Lopes-Cendes; Fernando Cendes
Journal:  J Neurol       Date:  2013-06-18       Impact factor: 4.849

9.  Machado Joseph disease is not an allele of the spinocerebellar ataxia 2 locus.

Authors:  E C Twist; L A Farrer; P M Macleod; J Radvany; S Chamberlain; R N Rosenberg; G A Rouleau
Journal:  Hum Genet       Date:  1994-03       Impact factor: 4.132

10.  Association between spinocerebellar ataxias caused by glutamine expansion and psychiatric and neuropsychological signals - a literature review.

Authors:  Uanda Cristina Almeida-Silva; Jaime Eduardo Cecílio Hallak; Wilson Marques Júnior; Flávia de Lima Osório
Journal:  Am J Neurodegener Dis       Date:  2013-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.